Methods regarding enhanced T-cell receptor-mediated tumor necrosis factor superfamily mRNA expression in peripheral blood leukocytes in patients with crohn's disease
First Claim
Patent Images
1. A method of determining whether a human having Crohn'"'"'s disease is likely to respond to immunosuppressive therapy, comprising:
- stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a first sample that comprises leukocytes from the human;
after the stimulation, measuring the amount of an mRNA encoding a tumor necrosis factor superfamily member in the first sample;
exposing leukocytes in vitro in a second sample comprising leukocytes from the human to a control stimulus;
measuring the amount of the mRNA in the second sample after exposing; and
determining a ratio of the amount of the mRNA in the first sample to the amount of the mRNA in the second sample, wherein a ratio of at least about 1.7;
1 indicates that the human is likely to respond to said immunosuppressive therapy.
4 Assignments
0 Petitions
Accused Products
Abstract
A method is disclosed for determining whether a human having Crohn'"'"'s disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn'"'"'s disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn'"'"'s disease is disclosed. A method of monitoring the disease state over time in Crohn'"'"'s disease patients is also disclosed.
33 Citations
13 Claims
-
1. A method of determining whether a human having Crohn'"'"'s disease is likely to respond to immunosuppressive therapy, comprising:
-
stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a first sample that comprises leukocytes from the human; after the stimulation, measuring the amount of an mRNA encoding a tumor necrosis factor superfamily member in the first sample; exposing leukocytes in vitro in a second sample comprising leukocytes from the human to a control stimulus; measuring the amount of the mRNA in the second sample after exposing; and determining a ratio of the amount of the mRNA in the first sample to the amount of the mRNA in the second sample, wherein a ratio of at least about 1.7;
1 indicates that the human is likely to respond to said immunosuppressive therapy. - View Dependent Claims (2, 3, 4, 5, 6, 12, 13)
-
-
7. A method of evaluating the state of Crohn'"'"'s disease in a human, comprising:
-
stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a first sample that comprises leukocytes and is obtained at a first time from the human; after the stimulation, measuring the amount of an mRNA encoding a tumor necrosis factor superfamily member in the first sample; exposing leukocytes in vitro to a control stimulus in a second sample comprising leukocytes obtained from the human at the first time; measuring the amount of the mRNA in the second sample after exposing; determining a first ratio of the amount of the mRNA in the first sample to the amount of the mRNA in the second sample; stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a third sample that comprises leukocytes and is obtained from the human at a second time that is subsequent to the first time; after the stimulation, measuring the amount of the mRNA in the third sample; exposing leukocytes in vitro to a control stimulus in a fourth sample comprising leukocytes obtained from the human at the second time; measuring the amount of the mRNA in the fourth sample after exposing; determining a second ratio of the amount of the mRNA in the third sample to the amount of the mRNA in the fourth sample; and comparing the first and second ratios, wherein a statistically significant difference in the first and second ratios is indicative of a change in the disease state. - View Dependent Claims (8, 9, 10, 11)
-
Specification